Cargando…
Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease
The loss of neuronal in the substantia nigra of the elderly contributes to striatal damage and plays a critical part in the common forms of neurodegenerative diseases such as Parkinson disease (PD). The deficit of dopamine is one of the most familiar neuropathological features of PD as well as α‐Syn...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529016/ https://www.ncbi.nlm.nih.gov/pubmed/37786563 http://dx.doi.org/10.1002/ibra.12011 |
_version_ | 1785111336285372416 |
---|---|
author | Yang, Ting‐Ting Liu, Yu‐Cong Li, Jing Xu, Hui‐Chan Li, Shun‐Lian Xiong, Liu‐Lin Wang, Ting‐Hua |
author_facet | Yang, Ting‐Ting Liu, Yu‐Cong Li, Jing Xu, Hui‐Chan Li, Shun‐Lian Xiong, Liu‐Lin Wang, Ting‐Hua |
author_sort | Yang, Ting‐Ting |
collection | PubMed |
description | The loss of neuronal in the substantia nigra of the elderly contributes to striatal damage and plays a critical part in the common forms of neurodegenerative diseases such as Parkinson disease (PD). The deficit of dopamine is one of the most familiar neuropathological features of PD as well as α‐Synuclein aggregation. The peripheral autonomic nervous system is also affected negatively during the course of the disease, although the subsistent of dyskinesias and else major motor characteristic deficits take significant role in the diagnostic methods during clinical practice, which is related to a number of non‐motor symptoms that might increase aggregate risks. Multiple pathways and mechanisms are involved in the molecular pathogenesis: α‐Synuclein, neuronal homeostasis, mitochondrial function, oxidative stress, as well as neuroinflammation. Investigations in the last few years for diagnostic biomarkers used neuroimaging, including single photon emission computed tomography as well as cutting‐edge magnetic resonance imaging techniques, which has been presented to facilitate discrepant diagnosis. Pharmacological treatment is also important and efficient in equal measure. In addition to reliance on striatal dopamine replacement therapy, many solutions that are used for motor or nonmotor symptoms in these patients are available. |
format | Online Article Text |
id | pubmed-10529016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105290162023-10-02 Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease Yang, Ting‐Ting Liu, Yu‐Cong Li, Jing Xu, Hui‐Chan Li, Shun‐Lian Xiong, Liu‐Lin Wang, Ting‐Hua Ibrain Reviews The loss of neuronal in the substantia nigra of the elderly contributes to striatal damage and plays a critical part in the common forms of neurodegenerative diseases such as Parkinson disease (PD). The deficit of dopamine is one of the most familiar neuropathological features of PD as well as α‐Synuclein aggregation. The peripheral autonomic nervous system is also affected negatively during the course of the disease, although the subsistent of dyskinesias and else major motor characteristic deficits take significant role in the diagnostic methods during clinical practice, which is related to a number of non‐motor symptoms that might increase aggregate risks. Multiple pathways and mechanisms are involved in the molecular pathogenesis: α‐Synuclein, neuronal homeostasis, mitochondrial function, oxidative stress, as well as neuroinflammation. Investigations in the last few years for diagnostic biomarkers used neuroimaging, including single photon emission computed tomography as well as cutting‐edge magnetic resonance imaging techniques, which has been presented to facilitate discrepant diagnosis. Pharmacological treatment is also important and efficient in equal measure. In addition to reliance on striatal dopamine replacement therapy, many solutions that are used for motor or nonmotor symptoms in these patients are available. John Wiley and Sons Inc. 2021-12-23 /pmc/articles/PMC10529016/ /pubmed/37786563 http://dx.doi.org/10.1002/ibra.12011 Text en © 2021 The Authors. Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Yang, Ting‐Ting Liu, Yu‐Cong Li, Jing Xu, Hui‐Chan Li, Shun‐Lian Xiong, Liu‐Lin Wang, Ting‐Hua Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease |
title | Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease |
title_full | Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease |
title_fullStr | Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease |
title_full_unstemmed | Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease |
title_short | Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease |
title_sort | advances in clinical basic research: performance, treatments, and mechanisms of parkinson disease |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529016/ https://www.ncbi.nlm.nih.gov/pubmed/37786563 http://dx.doi.org/10.1002/ibra.12011 |
work_keys_str_mv | AT yangtingting advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease AT liuyucong advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease AT lijing advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease AT xuhuichan advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease AT lishunlian advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease AT xiongliulin advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease AT wangtinghua advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease |